How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | 950220.KQ950220.KQ | ABBVAbbVie Inc. | Median of the restexcluding VRTX |
|---|---|---|---|---|
| Type | Company | Company | Company | |
| Price | $524.52▲ 9.87 (1.92%) | ₩1647.00▼ 41.00 (2.43%) | $285.19▲ 0.39 (0.14%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 8.7/10 | 2.0/10 | 7.0/10 | 4.5/10 |
| Market value | $133.22B | $11.04B | $503.46B | |
| Revenue | $12.00B | $94.8M | $61.16B | |
| Profit | $3.95B | -$31.80B | $4.23B | |
| Revenue growthChange in sales versus the prior year. | 8.9% | -44.3% | 8.6% | -17.9% |
| Gross marginShare of sales left after the direct cost of producing them. | 86.2% | 100.0% | 70.2% | 85.1% |
| Operating marginShare of sales left after running the business, before interest and tax. | 34.8% | -26596.5% | 24.6% | -13285.9% |
| Profit marginProfit kept from each dollar of sales. | 32.9% | -33531.4% | 6.9% | -16762.2% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 26.6% | -34003.6% | 29.1% | -16987.3% |
| Return on equityProfit against the owners' stake in the company. | 21.2% | -53.7% | -129.2% | -91.5% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 26.2% | -71.1% | 16.5% | -27.3% |
| P/E ratioPrice paid per dollar of annual profit. | 33.70x | — | 119.13x | 119.13x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | 35.69x | 35.69x |
| Price to book | 7.14x | 0.19x | -153.96x | -76.89x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.37x | 0.39x | -41.97x | -20.79x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 6/8 | 3/8 | 8/9 | 5.5 |
| Bankruptcy riskAltman Z-Score zone. | safe | distress | grey |
How VRTX compares with the others
- VRTX's operating margin of 34.8% is higher than the median of the other companies selected (-13285.9%).
- Its revenue grew faster than the median of the other companies selected: 8.9% against -17.9%.
- It trades at a lower P/E than the other company selected: 33.7x against 119.1x.
- Its liabilities are higher relative to equity than the median of the other companies selected: 0.4x against -20.8x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.